FDA approves Xanodyne's Lysteda for menorrhaegia

The FDA announced that it approved Xanodyne's Lysteda (tranexamic acid) as the first non-hormonal treatment for mennorhaegia.

Tranexamic acid was first approved in the US in 1986 as Cyklokapron, an injectable product used to reduce or prevent bleeding associated with tooth extraction in patients with haemophilia.

  • > The pharmaceutical industry and social media -- who leads, and who follows?
    Pharma and Social Media: The Leaders and Followers - click here to find out more
  • To read more Top Story articles, click here.